Oral Session 3-11A AML: Clinical siginificance of genetic abnormalities

[OS3-11A-5] The clinical features of Japanese de novo AML with RAS signal transduction pathway genes mutation

Shunsuke Yui¹, Hiroki Yamaguchi¹, Toshimitsu Ueki², Kensuke Usuki³, Yutaka Kobayashi⁴, Kenji Tajika⁵, Seiji Gomi⁵, Saiko Kurosawa⁶, Atsushi Marumo¹, Ikuko Omori¹, Yusuke Fujiwara¹, Masahiro Sakaguchi¹, Satoshi Wakita¹, Kunihito Arai¹, Tomoaki Kitano¹, Takahiro Fukuda⁶, Koiti Inokuchi¹ (1.Department of Hematology, Nippon Medical School, Tokyo, Japan, 2.Department of Hematology, Nagano Red Cross Hospital, Nagano, 3.Department of Hematology, NTT Medical Center, Tokyo, 4.Department of Hematology, Kyoto Second Red Cross Hospital, Kyoto, 5.Department of Hematology, Yokohama Minami Kyousai Hospital, Kanagawa, 6.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo)